Cardiac amyloidosis is far more common in everyday cardiology clinics than once believed: a new meta-analysis finds it in roughly one in eight patients with heart failure with preserved ejection fraction and about one in ten with severe aortic stenosis, according to a systematic review published in June in ESC Heart Failure.
The analysis, led by Alberto Aimo of the Health Sciences Interdisciplinary Center at Scuola Superiore Sant’Anna in Pisa, together with Vincenzo Castiglione, Giorgia Panichella and colleagues at Fondazione Toscana Gabriele Monasterio and the National Amyloidosis Centre at University College London, pooled 83 screening studies. As the paper states, the team searched PubMed/MEDLINE and EMBASE up to 10 August 2025 and grouped studies by clinical setting.
Why it matters now: cardiac amyloidosis (CA) was long dismissed as rare, a perception built on administrative databases rather than active case-finding.
With non-invasive imaging — chiefly bone scintigraphy — now able to flag transthyretin amyloidosis (ATTR) without biopsy, and with disease-modifying drugs available that slow progression, finding cases earlier has become the difference between preserving heart muscle and losing it. Treatments, the review notes, slow the disease but do not reliably reverse established myocardial damage.
CardioTeca, the Spanish cardiology outlet that covered the paper in detail, reported the key clinical message plainly: CA is not a rare disease in several common consultation settings, and screening should be targeted by context rather than applied universally.
Hidden amyloid deposits affect one in eight patients
- If you have heart failure with a stiff or “preserved” pumping heart, or severe narrowing of the aortic valve, roughly one in eight to one in ten patients like you may have hidden amyloid deposits — worth asking your cardiologist whether testing is appropriate.
- Bilateral carpal tunnel surgery in an older adult is a known early clue; the deposits in tendons can be a warning sign for the heart.
- Testing always involves two steps: a nuclear scan for the ATTR type, plus blood and urine tests to rule out the light-chain (AL) type — one scan alone is not enough.
Two ways of counting, one filter problem
A distinctive feature of the meta-analysis is how it handles diagnosis. In screening studies, CA can only be confirmed by bone scintigraphy plus monoclonal protein studies, cardiac MRI, or biopsy — but many studies tested only participants who passed a first filter, such as ECG or echocardiogram abnormalities, raised biomarkers, or amyloid found incidentally in surgical tissue.
So the authors calculated prevalence twice: across the whole cohort, including people never tested, and only among those who underwent confirmatory testing. The gap between the two figures shows how much that pre-filter inflates estimates.
One in eight HFpEF patients affected
In heart failure cohorts, pooled CA prevalence was 12.64% in the full cohort and 13.58% in the tested subgroup, CardioTeca reported. Almost all of it was ATTR — 11.43% — with light-chain amyloidosis contributing just 0.83%. In studies focused on heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), the figure held at 13.40% with both denominators: about one in eight patients.
In severe aortic stenosis, CA appeared in 9.55% of full cohorts and 11.62% of confirmed cases, again dominated by ATTR (9.49% versus 0.46% for AL). The highest prevalence sat in left ventricular hypertrophy and hypertrophic cardiomyopathy — 15.08% overall and 35.37% among those tested — though this rested on only four studies and showed extreme heterogeneity.
| Clinical setting | Whole cohort | Tested subgroup |
|---|---|---|
| LVH / hypertrophic cardiomyopathy | 15.08% | 35.37% |
| Heart failure (mainly HFpEF/HFmrEF) | 12.64% | 13.58% |
| Severe aortic stenosis | 9.55% | 11.62% |
| Orthopaedic cohorts (carpal tunnel) | 4.08% | 12.44% |
| No specific red flags | 1.76% | 7.76% |
| Non-cardiac bone scintigraphy | 0.49% | 0.49% |
Carpal tunnel: weak alone, powerful with red flags
The orthopaedic signal deserves special mention. In unselected carpal tunnel cohorts, prevalence was under 4%, but it more than tripled — to 13.47% in the carpal tunnel subgroup — once patients were selected for testing. Yield rose further when cardiac hypertrophy or other red flags coexisted. The authors suggest building CA assessment into carpal tunnel care pathways for older patients, particularly with bilateral involvement or ventricular hypertrophy.
One caution CardioTeca highlighted: the relative share of AL amyloidosis is higher in orthopaedic cohorts, so amyloid in a tendon or ligament should never simply be assumed to be ATTR.
Why ATTR-only screening fails
Across every setting, ATTR outnumbered AL — most starkly in non-cardiac bone scintigraphy (a ratio of 43.65) and aortic stenosis (20.59) — but AL never disappeared. Even in aortic stenosis, where the scan performs well, the authors insist that monoclonal protein studies — serum free light chains plus serum and urine immunofixation — remain essential to exclude AL and classify the subtype correctly. Strategies built around ATTR alone will miss light-chain disease.
A sex gap the criteria may be creating
Men dominated most tested cohorts — a male-to-female ratio of 2.77 in aortic stenosis and 2.10 in heart failure. Yet in unselected populations the ratio approached unity at 1.09. That contrast suggests current suspicion criteria find the disease preferentially in men. In women, the authors note, smaller ventricles, lower absolute wall thickness, and fixed wall-thickness thresholds that are less sensitive in female hearts may all contribute to underdiagnosis.
What the numbers cannot tell you
The authors themselves urge caution. Heterogeneity between studies was substantial in heart failure and aortic stenosis and extreme in the hypertrophy group, driven by differences in phenotype, ejection-fraction thresholds, age, ethnicity, valve severity, and whether confirmation was systematic or triggered only by red flags.
The figures should be read as indicators of diagnostic yield in each context, not as exact prevalences for any individual patient. The “no red flags” estimate rests on just three dissimilar studies and is not a population prevalence.
Scan alone insufficient for amyloidosis diagnosis
Bone scintigraphy for suspected ATTR involves a low-dose radioactive tracer and is generally well tolerated, but the diagnosis must never be pursued on a scan alone: monoclonal protein studies are mandatory first, because treating light-chain amyloidosis as ATTR would misdirect care entirely.
Anyone with heart failure, severe aortic stenosis, unexplained ventricular thickening, or bilateral carpal tunnel syndrome in later life should discuss with their cardiologist whether amyloidosis testing is warranted — not self-initiate it. Symptoms such as worsening breathlessness, fainting, or leg swelling warrant prompt professional evaluation.
The Pisa-based Fondazione Toscana Gabriele Monasterio, a public hospital and one of Italy’s leading cardiac imaging centres, performs 2,000 or more cardiac magnetic resonance scans a year, with amyloidosis among its main research topics alongside cardiomyopathies and inflammatory diseases.
The foundation runs structured clinical and research training in cardiac MRI, from one-month courses to year-long fellowships, and its research programmes are built in collaboration with the Sant’Anna School of Advanced Studies — the same Pisa institution where the meta-analysis’s lead author, Alberto Aimo, is based.
That pairing of a high-volume clinical scanning service with an academic research pipeline is precisely the kind of infrastructure that large screening efforts such as this one draw on.
Where screening goes next
The authors call for future studies to test every participant, or a predefined random sample, so the filter effect disappears.
For health systems — the NHS, which hosts the National Amyloidosis Centre among the study’s authors, and regulators such as the EMA and FDA overseeing the growing ATTR drug pipeline — the direction of travel is the same: targeted screening in HFpEF, severe aortic stenosis and hypertrophy, with attention to women and to AL, and diagnosis before myocardial damage becomes irreversible.
References
- Aimo A, Castiglione V, Panichella G, et al. Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis. ESC Heart Failure. 2026;13(5):xvag172. doi:10.1093/eschf/xvag172. PMID: 42325163.
- CardioTeca. Cribado de amiloidosis cardiaca en ICFEp, estenosis aórtica y túnel carpiano: resultados de un metaanálisis (Germán Cediel).
Related reading
- Alyssa Milano’s Nutrafol Hair Supplement Up to 30% Off for Black Friday
- 83-Year-Old Man With ICD Lead Endocarditis From E. faecalis Bacteremia
- Newtral Finds 39 Vietnam-Linked Facebook Pages Targeting Spanish Users (world-today-journal.com)
- Unvaccinated Pennsylvania Resident Dies, State Measles Toll Reaches Eight (archyworldys.com)